corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 14815

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: media release

Sales Through Retail Pharmacies (Twelve months to October 2008*)
2008 Dec
http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Retail_Drug_Monitor_December_2008.pdf


Full text:

NORTH AMERICA $225.5 billion up 1%
U.S.A. $208.4 billion up 1%
CANADA $17.0 billion up 6%
EUROPE (TOP 5) $116.4 billion up 2%
GERMANY $35.7 billion up 4%
FRANCE $31.1 billion up 1%
UK $16.4 billion down 2%
ITALY $17.5 billion up 1%
SPAIN $15.5 billion up 5%
JAPAN (including hospitals) $66.4 billion up 4%
LATIN AMERICA (TOP 3) $24.7 billion up 10%
BRAZIL $12.7 billion up 11%
MEXICO $8.8 billion up 3%
ARGENTINA $3.1 billion up 23%
AUSTRALIA/NZ $8.1 billion up 11%
The top 5 therapy classes at ATC3 level in the 12 months to October 2008
were:
1. C10A – Cholesterol & trigly. regulators
2. A2B – Antiulcerants
3. N6A – Antidepressants & mood stabilisers
4. N5A – Antipsychotics
5. N3A – Anti-epileptics
The top 5 products in the 12 months to October 2008 were:
1. Lipitor
2. Plavix
3. Nexium
4. Seretide/Advair
5. Enbrel
The top 5 corporations in the 12 months to October 2008 were:
1. Pfizer
2. GlaxoSmithKline
3. AstraZeneca
4. Novartis
5. Sanofi-Aventis

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








You are going to have many difficulties. The smokers will not like your message. The tobacco interests will be vigorously opposed. The media and the government will be loath to support these findings. But you have one factor in your favour. What you have going for you is that you are right.
- Evarts Graham
See:
When truth is unwelcome: the first reports on smoking and lung cancer.